Malignant Skin Neoplasm
NCI Definition: A primary or metastatic tumor involving the skin. Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumors to the skin include carcinomas and lymphomas. 
Malignant skin neoplasms most frequently harbor alterations in BRAF, TP53, CDKN2A, NRAS, and KMT2D .
BRAF Mutation, BRAF Exon 15 Mutation, TP53 Mutation, BRAF Codon 600 Missense, and TP53 Missense are the most common alterations in malignant skin neoplasm .
There are 3 clinical trials for malignant skin neoplasm, of which 3 are open and 0 are completed or closed. Of the trials that contain malignant skin neoplasm as an inclusion criterion, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).
T3011, pembrolizumab, and poly iclc are the most common interventions in malignant skin neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.